Tasquinimod
Myelofibrosis
Key Facts
About Active Biotech
Active Biotech is a Swedish biopharmaceutical company focused on modulating the immune system to treat cancer and inflammatory eye diseases. Its strategy centers on repurposing and advancing a portfolio of assets with extensive prior clinical data, including tasquinimod for hematological cancers and laquinimod for uveitis, to achieve efficient development in high-value niches. The company maintains a lean operational model, with key programs either fully owned or strategically partnered, such as naptumomab with NeoTX for solid tumors.
View full company profileAbout Active Biotech
Active Biotech is a Swedish biopharmaceutical company focused on modulating the immune system to treat cancer and inflammatory eye diseases. Its strategy centers on repurposing and advancing a portfolio of assets with extensive prior clinical data, including tasquinimod for hematological cancers and laquinimod for uveitis, to achieve efficient development in high-value niches. The company maintains a lean operational model, with key programs either fully owned or strategically partnered, such as naptumomab with NeoTX for solid tumors.
View full company profileTherapeutic Areas
Other Myelofibrosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Zavabresib (OPN-2853) | Opna Bio | Phase 1 |
| GB2064 | Galecto | Phase 2 |
| Exploratory Program | Cellarity | Pre-clinical |
| Myelofibrosis Program | Sequantrix | Pre-clinical |
| Jakafi (ruxolitinib) | Incyte | Marketed |
| KER-050 (Eltritercept) | Keros Therapeutics | Phase 2 |
| Selinexor | Karyopharm Therapeutics | Phase 3 |